Moguisteine is a non-narcotic anti-tussive compound that is used to prevent chronic cough. Moguisteine may derive its function through inhibition of rapidly-adapting irritant receptors or through activation of ATP-sensitive K+ channels in the tracheobronchial tract.
| Cas No. | 119637-67-1 |
|---|---|
| Purity | ≥98% |
| Formula | C16H21NO5S |
| Formula Wt. | 339.41 |
| IUPAC Name | ethyl3-[2-[(2-methoxyphenoxy)methyl]-1,3-thiazolidin-3-yl]-3-oxopropanoate |
| Synonym | +/-)-2-(2-Methoxyphenoxy)-methyl-3-ethoxycarbonylacetyl-1,3-thiazolidine; (R,S)-2-(2-Methoxyphenoxy)-methyl-3-ethoxycarbonyl-acetyl-1,3 thiazolidine |
| Melting Point | 72-76°C |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | M5727 Info Sheet PDF |
|---|
Luo YL, Li PB, Zhang CC, et al. Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure. Inflamm Res. 2013 Dec;62(12):1053-61. PMID: 24085318.
Morita K, Onodera K, Kamei J. Inhaled pinacidil, an ATP-sensitive K+ channel opener, and moguisteine have potent antitussive effects in guinea pigs. Jpn J Pharmacol. 2002 Jun;89(2):171-5. PMID: 12120760.
Sant'Ambrogio G, Sant'Ambrogio FB. Action of moguisteine on the activity of tracheobronchial rapidly adapting receptors in the dog. Eur Respir J. 1998 Feb;11(2):339-44. PMID: 9551735.
